611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Many Drugstores Won't Dispense Opioid Antidote as RequiredNew Cholesterol Guidelines Focus on Personalized ApproachAHA: Defibrillators Can Help Kids Survive Cardiac Arrest, TooFDA Will Ban Many Flavored E-CigarettesU.S. Smoking Rates Hit Record LowOnly a Quarter of Opioid Painkillers Taken After Most SurgeriesHome Health-Care Tests: Proceed With CautionFDA Takes on Flatulent CowsWhy Bystanders Are Less Likely to Give CPR to WomenCellphone Radiation Tied to Upped Odds for Cancer -- in RatsHealth Tip: FDA Discusses Possible Risks of Bodybuilding ProductsU.S. Hospitals Making Headway Against InfectionsAfter Mass Shootings, Blood Donations Can Go UnusedLead in Hair Dyes Must Go: FDAIn California, Some Doctors Sell 'Medical Exemptions' for Kids' VaccinationsGot Unused Prescription Meds? Saturday Is National Drug Take-Back DayFDA Too Quick to Call BPA Chemical Safe, Health Experts SayIs Crowdfunding Too Often Used for Bogus Treatments?Many Supplements Still Contain Dangerous Stimulants: StudyTapping Into TelehealthMenthol Cig Ban Didn't Spur Black Market Sales: StudyHip-Hop Loaded With Pot, Cigarette ReferencesWhite House Wants Prices in Drug Ads, But Big Pharma Fights BackMany Supplements Contain Unapproved, Dangerous Ingredients: StudyE-Cigs Continue to Spark Debate Over Health Risks/BenefitsClinical Trials Need More VolunteersGetting Your Medical Records Might Not Be EasyMost People Don't Know if They Have Genetic Risk for CancerConsumer Reports Says Warnings About Tainted Beef Don't Go Far EnoughThe Physician Assistant Will See You NowCoffee Shop Workers on Front Lines of Opioid CrisisDozens of Medical Groups Join Forces to Improve DiagnosesDoes Big Pharma Hike Prices When Meds Are in Short Supply?FDA Gets Tough on Juul, Other E-Cigarette Makers'No Documented Reason' for 1 in 3 Outpatient Opioid Rxs: StudyUrgent Care Centers Ease ER Burden in U.S.Poor Health Care Linked to 5 Million Deaths Worldwide a Year'Million Hearts' Project Aims to Prevent 1 Million Cardiac CrisesDoctor Burnout Likely to Impair CareHomelessness Takes Toll on Kids' Health Even Before They're BornFDA Warns of Dangers of Liquid Nitrogen in Food, DrinksStates Struggle With Onslaught of Opioid OD DeathsAHA: Why More Americans Are Kicking the Smoking HabitMonitoring System for Underage Tobacco Sales Falls Short: StudyHundreds of Human, Pet Homeopathy Products RecalledAHA: CPR Training at School Now Required in 38 StatesGovernment Rules Aimed at Curbing Opioid Prescriptions May Have BackfiredGut Enzyme Could Help Solve U.S. Blood ShortagesHealth Tip: Making an Emergency CallFrom Pigs to Peacocks, What's Up With Those 'Emotional-Support Animals'?
Questions and AnswersLinksBook Reviews
Related Topics

Health Insurance
Healthcare

Nonprofit Manufacturer Could Keep Generic Drug Costs Down


HealthDay News
Updated: May 16th 2018

new article illustration

WEDNESDAY, May 16, 2018 (HealthDay News) -- A nonprofit manufacturer could help keep generic drug prices down and maintain their supply, according to a perspective piece published in the May 17 issue of the New England Journal of Medicine.

Dan Liljenquist, J.D., from Intermountain Healthcare in Salt Lake City, and colleagues discuss generic drug market failure, whereby a generic drug manufacturer increases the drug price, which can compromise care.

The authors note that other manufacturers do not enter the seemingly lucrative generic drug market partly because of the initial investment required and cost of obtaining U.S. Food and Drug Administration approval. In addition, there is concern that once a second drug is approved for the condition, the manufacturer of the original generic will reduce the price of its product. One solution is establishment of a nonprofit generic drug manufacturer with the aim of producing affordable versions of essential drugs and ensuring a stable supply. A consortium of hospitals and health plans is currently developing a nonprofit generic drug manufacturer named Project Rx. The nonprofit manufacturer, which has a legal constraint that it cannot distribute earnings, will pursue a cost-plus strategy, generating enough revenue to cover costs and maintain a limited surplus for financial viability rather than profit maximization.

"We believe that Project Rx may drive other nonprofit and for-profit manufacturers to enter generic-drug markets, compete among themselves, and collectively improve market efficiency and broaden access to generic drugs," the authors write.

One author disclosed serving as a volunteer on the advisory committee of Project Rx.

Abstract/Full Text